C4 Therapeutics Financials
| CCCC Stock | USD 2.72 0.05 1.87% |
Understanding current and past C4 Therapeutics Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of C4 Therapeutics' financial statements are interrelated, with each one affecting the others. For example, an increase in C4 Therapeutics' assets may result in an increase in income on the income statement.
Please note, the presentation of C4 Therapeutics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, C4 Therapeutics' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of C4 Therapeutics' management manipulating its earnings.
C4 Therapeutics Stock Summary
C4 Therapeutics competes with Foghorn Therapeutics, Shattuck Labs, Monte Rosa, Kymera Therapeutics, and Nurix Therapeutics. C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts. C4 Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 121 people.Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Instrument | USA Stock View All |
| Exchange | NASDAQ Exchange |
| ISIN | US12529R1077 |
| CUSIP | 12529R107 |
| Location | Massachusetts; U.S.A |
| Business Address | 490 Arsenal Way, |
| Sector | Biotechnology |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Website | www.c4therapeutics.com |
| Phone | 617 231 0700 |
| Currency | USD - US Dollar |
C4 Therapeutics Key Financial Ratios
CCCC Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining C4 Therapeutics's current stock value. Our valuation model uses many indicators to compare C4 Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across C4 Therapeutics competition to find correlations between indicators driving C4 Therapeutics's intrinsic value. More Info.C4 Therapeutics is rated fourth in return on equity category among its peers. It is rated fifth in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the C4 Therapeutics' earnings, one of the primary drivers of an investment's value.C4 Therapeutics Systematic Risk
C4 Therapeutics' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. C4 Therapeutics volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was five with a total number of output elements of fifty-six. The Beta measures systematic risk based on how returns on C4 Therapeutics correlated with the market. If Beta is less than 0 C4 Therapeutics generally moves in the opposite direction as compared to the market. If C4 Therapeutics Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one C4 Therapeutics is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of C4 Therapeutics is generally in the same direction as the market. If Beta > 1 C4 Therapeutics moves generally in the same direction as, but more than the movement of the benchmark.
About C4 Therapeutics Financials
What exactly are C4 Therapeutics Financials? Typically, a company's financial statements are the reports that show the financial position of the company. Three primary documents fall into the category of financial statements. These documents include C4 Therapeutics' income statement, its balance sheet, and the statement of cash flows. Potential C4 Therapeutics investors and stakeholders use financial statements to determine how well the company is positioned to perform in the future. Although C4 Therapeutics investors may use each financial statement separately, they are all related. The changes in C4 Therapeutics's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on C4 Therapeutics's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.C4 Therapeutics September 6, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of C4 Therapeutics help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of C4 Therapeutics. We use our internally-developed statistical techniques to arrive at the intrinsic value of C4 Therapeutics based on widely used predictive technical indicators. In general, we focus on analyzing CCCC Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build C4 Therapeutics's daily price indicators and compare them against related drivers.
| Downside Deviation | 4.6 | |||
| Information Ratio | 0.1293 | |||
| Maximum Drawdown | 39.07 | |||
| Value At Risk | (7.44) | |||
| Potential Upside | 12.5 |
Complementary Tools for CCCC Stock analysis
When running C4 Therapeutics' price analysis, check to measure C4 Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy C4 Therapeutics is operating at the current time. Most of C4 Therapeutics' value examination focuses on studying past and present price action to predict the probability of C4 Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move C4 Therapeutics' price. Additionally, you may evaluate how the addition of C4 Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges |